Authorization Holder Scheme To Shake Up China R&D, Production
This article was originally published in PharmAsia News
China is to introduce on a pilot basis in 10 provinces a new marketing authorization holder scheme, under which a manufacturing site will no longer be required for a drug approval. The change will allow researchers and institutions to hold approvals and is expected to spark changes in both the R&D and contract manufacturing sectors.
Register for our free email digests: